Theseus Pharmaceuticals: Orbimed-Backed Ex-ARIAD Team Developing Next-Gen TKISeeking Alpha • 04/27/23
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual MeetingPRNewsWire • 04/26/23
Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?Zacks Investment Research • 04/04/23
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual SymposiumPRNewsWire • 03/28/23
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial ResultsPRNewsWire • 03/09/23
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma ConferencePRNewsWire • 02/07/23
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development ProgramPRNewsWire • 01/05/23
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR SymposiumPRNewsWire • 10/26/22
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung CancerPRNewsWire • 10/03/22
Theseus Pharmaceuticals to Participate at Upcoming September Investor ConferencesPRNewsWire • 09/06/22
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial ResultsPRNewsWire • 08/11/22
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare ConferencePRNewsWire • 08/03/22
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial ResultsPRNewsWire • 05/12/22
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual MeetingPRNewsWire • 04/08/22
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare ConferencePRNewsWire • 04/05/22
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial ResultsPRNewsWire • 03/10/22
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual MeetingPRNewsWire • 03/08/22
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare ConferencePRNewsWire • 02/09/22
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)PRNewsWire • 02/02/22